Novedades en Cardiopatía Isquémica en los principales congresos del año
24/11/15 18:00h - 20:00h Casa del Corazón, Madrid
Intervencionismo en Cardiopatía Isquémica
Dr. Iván Núñez Gil, Hospital Universitario Clínico San Carlos (Madrid)
8. TOTAL, en conclusión
• La trombectomía rutinaria NO reduce mortalidad CV, infarto, shock o
ICC a un año
• Se asocia a un riesgo aumentado de ictus.
• NO se recomienda en todos los pacientes.
9. TOTAL, en conclusión
• La trombectomía rutinaria NO reduce mortalidad CV, infarto, shock o
ICC a un año
• Se asocia a un riesgo aumentado de ictus (causa controvertida).
• NO se recomienda en todos los pacientes.
En España bajó un 4,1 % el uso de tromboaspirador
de 2013-a 2014 (61,2% de ICPp)
18. 1:1
1:1
NSTEACS or STEMI with invasive management
Aspirin+P2Y12 blocker
Trans-Femoral
Access
Heparin
±GPI
Bivalirudin
Mono-Tx
Stop
Infusion
Prolong≥ 6 hs
infusion
1:1
Trans-Radial
Access
MATRIX Access
Q: Is TRI superior to TFI ?
MATRIX Program registered at
ClinicalTrials.gov, number NCT01433627
Am Heart J. 2014 Dec;168(6):838-45.e6.
20. Cross Over and Procedural
Success Rates
94.1% of radial and 97.4% of
femoral cohorts received
respective treatment as allocated
In 5.8% of radial and 2.3% of TF
cohort the allocated access was
attempted but failed.
In 3 (0.1%) in the radial and 13
(0.3%) patients in the femoral
groups the allocated access was
not attempted
P=0.77P<0.001
*
*: TIMI <3 and/or % final stenosis >30%
%
25. REGISTRO RAID.
• Disección tipo A (74/108083).
• Incidencia 0,06%. En terapéuticos (0,098%)
• Varones, procedimientos complejos y terapéuticos coronarios.
• Afectan coronarias en 60%; sobre todo CD.
• Mortalidad baja.
• Aorta: conservadora
• Afectación coronaria: stenting.
• Restitutio ad integrum, sin recurrencias.
49. Stent sin polímero.
Selectively Micro-Structured Surface Holds
Drug in Abluminal Surface Structures
Potential Advantages:
Avoid any possible polymer-related adverse effects
Rapid drug transfer to vessel wall (98% within one month2)
Safe to shorten DAPT?
BA9TM
Drug 10 Times More
Lipophilic than Sirolimus1
Sirolimus Zotarolimus Everolimus Biolimus A9TM
0
20
40
60
80
100 %
+/- 2.8% (valid for all drugs test)
1. Data on file at Biosensors Intl; 2. Tada et al., Circ Cardiovasc Interv 2010;3;174-183
50. Inclusion Criteria Applied (1.7 criteria / patient)
1,1
0,9
1,2
1,6
3,1
3,4
3,8
9,7
15,2
15,3
17,9
36,7
64,5
1,6
0,8
2
1,5
2,8
3,9
2,7
9,9
16
17,4
20,2
35,6
64,1
0 10 20 30 40 50 60 70
Prior intracerebral bleed
Severe liver disease
Stroke < 1 year
Thrombocytopenia
NSAID or steroids
DAPT compliance
Hospital for bleeding
Cancer
Anemia or recent TF
Surgery soon
Renal failure
Oral anticoagulants
Age ≥ 75
BMS
DCS
51. DISEÑO
Prospective, double-blind randomized (1:1) trial
2466 High bleeding risk (HBR) PCI patients
vs.
DAPT mandated for 1 month only, followed by long-term SAPT
BioFreedom™
DCS
Gazelle™
BMS
• Primary safety endpoint:
Composite of cardiac death, MI, definite / probable stent thrombosis
at 1 year (non-inferiority then superiority)
• Primary efficacy endpoint:
Clinically-driven TLR at 1 year (superiority)
52. Primary Efficacy Endpoint (Clinically-Driven TLR)
0
90 180 270 390
CumulativePercentagewithEvent
3
6
9
12
Days0
9.8%
5.1%
p for superiority < 0.001
390 days chosen for assessing primary EP to capture potential evens driven by the 360 day FU contact
%
Number at Risk
DCS 1221 1167 1130 1098 1053
BMS 1211 1131 1072 1034 984
53. Primary Efficacy Endpoint
Primary Efficacy Endpoint
DCS
(n=1221)
BMS
(n=1211)
Clinically driven TLR at 390 days 59 (5.1%) 113 (9.8%)
Difference:
• -4.8% (95% CI = -6.9% to -2.6%)
• HR 0.50, (95% CI = 0.37 – 0.69)
• p<0.001 for superiority
54. Primary Safety Endpoint (Cardiac Death, MI, ST)
0
90 180 270 390
CumulativePercentagewithEvent
3
6
9
12
Days0
12.9%
9.4%
p = 0.005 for superiority
15
390 days chosen for assessing primary EP to capture potential events driven by the 360 day FU contact
%
Number at Risk
DCS 1221 1146 1105 1081 1045
BMS 1211 1115 1066 1037 1000
55. Primary Safety Endpoint
Primary Safety Endpoint*
DCS
(n=1221)
BMS
(n=1211)
Cardiac Death, Myocardial Infarction,
or Stent Thrombosis at 390 days
112 (9.4%) 154 (12.9%)
Risk difference:
• -3.6% (95% CI -6.1% to -1.0%)
• HR 0.71, (95% CI = 0.56 – 0.91)
• p < 0.0001 for non-inferiority
• p = 0.005 for superiority
* 3rd Universal definition of MI, Thygesen K et al Circulation 2012;126:2020 –2035
ARC definition, Cutlip D et al. Circulation 2007; 115: 2344-51
58. Cómo estamos en España?
• Datos voluntarios no auditados de 106 hospitales.
1447/millón habs
(1419 en 2013)
59. Cómo estamos en España?
• Datos voluntarios no auditados de 106 hospitales.
382/millón habs
(395 en 2013)
PERO MÁS ANGIOPLASTIA PRIMARIA: 14679
(13899, en 2013)
60. Stents implantados, en España
• 94458 (casi 5000 menos que en 2013).
• Ratio stent/paciente <1,4 (1,5 en 2013, 1,8 en 2008).
• Más farmacoactivos, 64057: 67,8% (61,5% en 2013).
• Más BVS: 2424; 2,5% (1384 en 2013).